SI3107914T1 - Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba - Google Patents

Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba

Info

Publication number
SI3107914T1
SI3107914T1 SI201530714T SI201530714T SI3107914T1 SI 3107914 T1 SI3107914 T1 SI 3107914T1 SI 201530714 T SI201530714 T SI 201530714T SI 201530714 T SI201530714 T SI 201530714T SI 3107914 T1 SI3107914 T1 SI 3107914T1
Authority
SI
Slovenia
Prior art keywords
pyrazolo
pyrimidine
therapeutic use
diamine compounds
cdk inhibitors
Prior art date
Application number
SI201530714T
Other languages
English (en)
Slovenian (sl)
Inventor
Alexander Bondke
Sebastian Kroll
Anthony Barrett
Matthew Fuchter
Brian Slafer
Simak Ali
Charles Coombes
James Patrick Snyder
Original Assignee
Cancer Research Technology Limited
Ip2Ipo Innovations Limited
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Limited, Ip2Ipo Innovations Limited, Emory University filed Critical Cancer Research Technology Limited
Publication of SI3107914T1 publication Critical patent/SI3107914T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201530714T 2014-02-21 2015-02-20 Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba SI3107914T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201403093A GB201403093D0 (en) 2014-02-21 2014-02-21 Therapeutic compounds and their use
EP15706282.9A EP3107914B8 (en) 2014-02-21 2015-02-20 Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
PCT/GB2015/050494 WO2015124941A1 (en) 2014-02-21 2015-02-20 Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use

Publications (1)

Publication Number Publication Date
SI3107914T1 true SI3107914T1 (sl) 2019-05-31

Family

ID=50482596

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530714T SI3107914T1 (sl) 2014-02-21 2015-02-20 Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba

Country Status (23)

Country Link
US (4) US9932344B2 (OSRAM)
EP (1) EP3107914B8 (OSRAM)
JP (1) JP6498212B2 (OSRAM)
CN (1) CN106103445B (OSRAM)
AU (1) AU2015220560B2 (OSRAM)
BR (1) BR112016018633B1 (OSRAM)
CA (1) CA2939786C (OSRAM)
CY (1) CY1121588T1 (OSRAM)
DK (1) DK3107914T3 (OSRAM)
ES (1) ES2721268T3 (OSRAM)
GB (1) GB201403093D0 (OSRAM)
HR (1) HRP20190685T1 (OSRAM)
HU (1) HUE043122T2 (OSRAM)
LT (1) LT3107914T (OSRAM)
ME (1) ME03427B (OSRAM)
NZ (1) NZ724323A (OSRAM)
PL (1) PL3107914T3 (OSRAM)
PT (1) PT3107914T (OSRAM)
RS (1) RS58704B1 (OSRAM)
SI (1) SI3107914T1 (OSRAM)
SM (1) SMT201900266T1 (OSRAM)
TR (1) TR201905647T4 (OSRAM)
WO (1) WO2015124941A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2015337607B2 (en) 2014-10-31 2020-04-09 Ube Corporation Substituted dihydropyrrolopyrazole compound
AU2015367531B2 (en) 2014-12-17 2020-04-30 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists
WO2016130920A2 (en) * 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
JP6787314B2 (ja) 2015-06-15 2020-11-18 宇部興産株式会社 置換ジヒドロピロロピラゾール誘導体
US20200123499A1 (en) 2015-12-02 2020-04-23 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
AU2017319500C1 (en) 2016-08-31 2022-10-20 Les Laboratoires Servier Inhibitors of cellular metabolic processes
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
AU2018312836B2 (en) * 2017-08-07 2022-12-08 Joint Stock Company "Biocad" Novel heterocyclic compounds as CDK8/19 inhibitors
US20200197392A1 (en) * 2017-08-15 2020-06-25 The Brigham & Women's Hospital, Inc. Compositions and methods for treating tuberous sclerosis complex
GB201715194D0 (en) * 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
CN112313235A (zh) * 2018-04-11 2021-02-02 奎利恩特有限公司 作为周期蛋白依赖性激酶的选择性抑制剂的吡唑并-三嗪和/或吡唑并-嘧啶衍生物
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
AU2019291935A1 (en) 2018-06-29 2021-02-04 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
AU2019370200B2 (en) 2018-10-30 2024-12-19 Kronos Bio, Inc. Compounds, compositions, and methods for modulating CDK9 activity
WO2020100944A1 (ja) 2018-11-14 2020-05-22 宇部興産株式会社 ジヒドロピロロピラゾール誘導体
CN109860354B (zh) * 2018-12-28 2020-05-19 南京邮电大学 同质集成红外光子芯片及其制备方法
US20220144841A1 (en) * 2019-03-13 2022-05-12 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
AU2020311297A1 (en) * 2019-07-10 2022-02-03 Aucentra Therapeutics Pty Ltd DERIVATIVES OF 4-(IMIDAZO[l,2-a]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS
WO2021087138A1 (en) * 2019-10-29 2021-05-06 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
GB201918541D0 (en) * 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
EP4114528A1 (en) * 2020-03-06 2023-01-11 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
JP7657943B2 (ja) * 2021-01-22 2025-04-07 上海海雁医薬科技有限公司 置換ピラゾロ[1,5-a]ピリミジン-7-アミン誘導体、その組成物及び医薬上の使用
AR125798A1 (es) 2021-05-07 2023-08-16 Kymera Therapeutics Inc Degradadores cdk2 y usos de los mismos
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
WO2023096922A1 (en) * 2021-11-24 2023-06-01 Kronos Bio, Inc. Polymorphic and salt forms of (ls,3s)-n1-(5-(pentan-3- yl)pyrazolo[l,5-a]pyrimidin-7-yl)cyclopentane-l,3-diamine
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases
WO2024174949A1 (zh) * 2023-02-20 2024-08-29 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
TW202500147A (zh) 2023-06-27 2025-01-01 美商亞文納營運公司 雌激素受體降解劑與cdk7抑制劑之組合
WO2025057087A1 (en) 2023-09-11 2025-03-20 Assia Chemical Industries Ltd. Solid state forms of samuraciclib
WO2025208097A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2025208104A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4794793B2 (ja) 1999-12-28 2011-10-19 ファーマコペイア, インコーポレイテッド N−ヘテロ環TNF−α発現阻害剤
EP1537116B1 (en) 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
AU2004210149A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
MXPA05008955A (es) 2003-02-28 2006-02-22 Teijin Pharma Ltd Derivados de pirazolo [1,5-a] pirimidina.
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
TWI421078B (zh) * 2005-10-06 2014-01-01 Merck Sharp & Dohme 關卡激酶抑制劑及其用途
EP2170073A4 (en) * 2007-06-05 2011-07-27 Univ Emory SELECTIVE INHIBITORS FOR CYCLINE-RELATED KINASES
US8575177B2 (en) * 2009-12-04 2013-11-05 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
EP3409278B8 (en) * 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use

Also Published As

Publication number Publication date
US10927119B2 (en) 2021-02-23
US20160362410A1 (en) 2016-12-15
HRP20190685T1 (hr) 2019-06-14
AU2015220560B2 (en) 2019-05-16
DK3107914T3 (en) 2019-04-29
EP3107914A1 (en) 2016-12-28
JP2017506250A (ja) 2017-03-02
NZ724323A (en) 2022-02-25
AU2015220560A1 (en) 2016-10-06
US20180273540A1 (en) 2018-09-27
HUE043122T2 (hu) 2019-08-28
US10414772B2 (en) 2019-09-17
ME03427B (me) 2020-01-20
SMT201900266T1 (it) 2019-07-11
PL3107914T3 (pl) 2019-09-30
EP3107914B1 (en) 2019-01-30
US20200055862A1 (en) 2020-02-20
GB201403093D0 (en) 2014-04-09
PT3107914T (pt) 2019-05-20
RS58704B1 (sr) 2019-06-28
CN106103445B (zh) 2019-08-09
WO2015124941A1 (en) 2015-08-27
CA2939786A1 (en) 2015-08-27
CA2939786C (en) 2022-03-08
CN106103445A (zh) 2016-11-09
US9932344B2 (en) 2018-04-03
BR112016018633B1 (pt) 2022-08-30
LT3107914T (lt) 2019-05-27
BR112016018633A2 (OSRAM) 2017-08-08
US11566029B2 (en) 2023-01-31
JP6498212B2 (ja) 2019-04-10
CY1121588T1 (el) 2020-05-29
EP3107914B8 (en) 2019-07-17
ES2721268T3 (es) 2019-07-30
TR201905647T4 (tr) 2019-05-21
US20210253583A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
SI3107914T1 (sl) Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba
HUS2200054I1 (hu) 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése
IL272031A (en) Bicyclic pyrazolo and triazolo compounds as JAK kinase inhibitors
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
IL247949A0 (en) New histories of pyrazolopyrimidines and their use as malt1 inhibitors
SI3419978T1 (sl) Derivati pirazolo(1,5-A)pirazin-4-ila kot zaviralci z janusom povezane kinaze (JAK)
HK1245247A1 (zh) 溴结构域的抑制剂
HUE051898T2 (hu) Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
ZA201701207B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
ZA201704727B (en) New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer
IL253427B (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose